prime-2-cov_beta
VaccineexperimentalCOVID-19
Clinical trial activity
2 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 20, 2022 (NCT05367843)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05389319 | Phase 1 | Jun 24, 2022 | FGK Clinical Research GmbH, Staburo GmbH, University of Tuebingen, Viedoc Technologies AB, VisMederi srl |
| NCT05367843 | Phase 1 | Jun 20, 2022 | Speransa Therapeutics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| FGK Clinical Research GmbH | For profit | 1 | 0 | 1 | 2022 |
| Speransa Therapeutics | For profit | 1 | 1 | 1 | 2022 |
| Staburo GmbH | For profit | 1 | 0 | 1 | 2022 |
| University of Tuebingen | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Viedoc Technologies AB | For profit | 1 | 0 | 1 | 2022 |
| VisMederi srl | For profit | 1 | 0 | 1 | 2022 |
6 organizations
Page 1 / 1